Description

Energoton (trimetazidine dihydrochloride) Coated Tablets 0.02 g. №60

Ingredients

Active ingredient: Trimetazidine dihydrochloride 0.02 g per coated tablet.

Dosage

Dosage: The usual dose is 1 tablet three times a day, preferably taken with meals.

Indications

Indications: Energoton tablets are indicated for the symptomatic treatment of stable angina pectoris.

Contraindications

Contraindications: Do not use Energoton tablets in patients with Parkinson’s disease, tremors, or hyperthyroidism.

Directions

Directions: Swallow the tablet whole with a glass of water. Do not crush or chew the tablet.

Scientific Evidence

Energoton (trimetazidine dihydrochloride) has been extensively studied for its efficacy in the treatment of angina pectoris. Clinical trials have shown that trimetazidine, the active ingredient in Energoton, improves exercise tolerance, reduces the frequency of angina attacks, and enhances the quality of life in patients with stable angina.

Additional Information

It is important to note that Energoton should be used as part of a comprehensive treatment plan for angina, including lifestyle modifications and other medications as prescribed by a healthcare provider.

Pharmacological Effects: Trimetazidine acts by shifting myocardial metabolism from fatty acid oxidation to glucose oxidation, thereby preserving energy production in the ischemic myocardium. This results in improved cardiac function and reduced ischemic damage.

Clinical Trials: A meta-analysis published in the European Heart Journal demonstrated that trimetazidine therapy significantly reduced the frequency of angina attacks and nitroglycerin consumption in patients with stable angina. The study concluded that trimetazidine is a valuable addition to the treatment of chronic angina.